IE
FBRX icon

Israel Englander’s Forte Biosciences FBRX Stock Holding History

Israel Englander’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Buy
655,199
+317,216
+94% +$7.52M 0.01% 1964
2026
Q1 		$8.75M Buy
337,983
+91,298
+37% +$2.63M ﹤0.01% 2299
2025
Q4 		$6.73M Buy
246,685
+126,873
+106% +$2.22M ﹤0.01% 2690
2025
Q3 		$1.8M Buy
119,812
+47,696
+66% +$549K ﹤0.01% 4158
2025
Q2 		$932K Buy
72,116
+57,511
+394% +$495K ﹤0.01% 4462
2025
Q1 		$113K Buy
+14,605
New +$172K ﹤0.01% 5417
2023
Q3 		– Sell
-2,284
Closed -$59.4K – 6246
2023
Q2 		$59.4K Sell
2,284
-1,665
-42% -$43.3K ﹤0.01% 5439
2023
Q1 		$100K Buy
3,949
+1,245
+46% +$31.3K ﹤0.01% 5426
2022
Q4 		$68K Sell
2,704
-2,540
-48% -$65.1K ﹤0.01% 5699
2022
Q3 		$140K Buy
5,244
+2,884
+122% +$91.6K ﹤0.01% 5836
2022
Q2 		$77K Buy
+2,360
New +$75K ﹤0.01% 6032
2022
Q1 		– Sell
-11,240
Closed -$601K – 7067
2021
Q4 		$601K Sell
11,240
-8,970
-44% -$603K ﹤0.01% 4885
2021
Q3 		$1.5M Buy
20,210
+19,447
+2,549% +$10.8M ﹤0.01% 4241
2021
Q2 		$641K Sell
763
-5,673
-88% -$5.11M ﹤0.01% 5082
2021
Q1 		$5.51M Buy
6,436
+4,875
+312% +$3.99M ﹤0.01% 2463
2020
Q4 		$1.42M Buy
+1,561
New +$1.47M ﹤0.01% 3488
2020
Q1 		– Sell
-257
Closed -$51K – 4045
2019
Q4 		$51K Buy
257
+163
+173% +$36.9K ﹤0.01% 4095
2019
Q3 		$23K Sell
94
-22
-19% -$33.4K ﹤0.01% 4085
2019
Q2 		$290K Buy
+116
New +$344K ﹤0.01% 3561
2019
Q1 		– Sell
-81
Closed -$248K – 4061
2018
Q4 		$248K Sell
81
-143
-64% -$616K ﹤0.01% 3308
2018
Q3 		$1.31M Buy
224
+170
+315% +$647K ﹤0.01% 2722
2018
Q2 		$188K Sell
54
-37
-41% -$135K ﹤0.01% 3570
2018
Q1 		$402K Buy
+91
New +$421K ﹤0.01% 3102

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Israel Englander's FBRX Position: Q2 2026 in Review

Israel Englander increased its Forte Biosciences (FBRX) stake by 94% in Q2 2026, buying an estimated $7.52M and bringing the position to 655,199 shares worth $13.9M. The position accounts for 0.01% of the portfolio, ranked #1964.

Israel Englander first reported a position in FBRX in Q1 2018 and has held it in 23 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Israel Englander held 655,199 shares of Forte Biosciences worth $13.9M as of Q2 2026.
  • Israel Englander bought 317,216 Forte Biosciences shares in Q2 2026, an estimated $7.52M.
  • Forte Biosciences made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1964 holding.
  • Israel Englander first reported a position in Forte Biosciences in Q1 2018 and has held it in 23 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.